TRIP13 is identified as a prognosis biomarker for renal clear cell carcinoma and promotes renal cell carcinoma cell proliferation, migration and invasion

被引：1
作者：
Qian, Benjiang [1 ]
Ying, Xiaoyan [2 ]
Yang, Guang [1 ]
Li, Huizhang [3 ,4 ]
Tan, Jianming [1 ]
机构：
[1] Xiamen Univ, Sch Med, Fujian Prov Key Lab Transplant Biol, Dept Urol,Dongfang Hosp,Hosp Joint Logist Team 90, Fuzhou 350025, Peoples R China
[2] Fujian Med Univ, Dept Neurol, Affiliated Mindong Hosp, Fuan 355000, Peoples R China
[3] Fujian Med Univ, Inst Ningde Urol Res, Affiliated Mindong Hosp, Fuan 355000, Peoples R China
[4] Fujian Med Univ, Dept Urol, Affiliated Mindong Hosp, Fuan 355000, Peoples R China
来源：
BIOCELL | 2021年 / 45卷 / 03期
关键词：
Renal cell carcinoma; Bioinformatics; TRIP13; Proliferation; Migration; Invasion; Metastasis; CANCER STATISTICS; SORAFENIB; SURVIVAL; CHINA;
D O I：
10.32604/biocell.2021.014972
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
This work aimed to discover new therapeutic targets in renal clear cell carcinoma by bioinformatics and detect the effect of candidate gene TRIP13 in renal cell carcinoma (RCC) cell proliferation, migration, and invasion. Differentially expressed mRNAs were screened based on The Cancer Genome Atlas (TCGA)-Kidney Renal Clear Cell Carcinoma (KIRC) databases, and functional enrichments, survival analysis, receiver operating characteristic curve (ROC), and Protein-Protein Interaction (PPI) protein interaction analysis were performed by R software to screen the candidate gene TRIP13. Then, the expression of candidate gene TRIP13 in 92 pairs of cancer and adjacent normal tissues of renal clear cell carcinoma patients were detected by qRT-PCR, western blotting, and immunochemical analysis. The TRIP13 level and clinicopathological characteristics of patients with renal clear cell carcinoma were analyzed. Using 186-O and ACHN RCC cell lines with TRIP13 overexpressing or downregulating, the effect of TRIP13 on cell viability and proliferation were detected by CCK8 and EdU staining, respectively. The migration and invasion were detected by Transwell assays. A total of 19858 differentially expressed genes, 5823 differentially expressed genes, 3657 up-regulated genes, and 2166 down-regulated genes were identified. TRIP13 was closed associated with cell cycle regulation, and survival and prognosis of renal clear cell carcinoma were selected as a candidate gene. The mRNA and protein levels of TRIP13 in cancer tissues were higher than that in adjacent normal tissues. TRIP13 level was significantly associated with tumor size, tumor stage, Fuhrman grade, and lymph node metastasis. TRIP13 overexpression significantly increased cell viability, proliferation, migration, and invasion, while downregulating of TRIP13 had opposite effects in both 186-O and ACHN cells. Therefore, TRIP13 promotes RCC proliferation and metastasis, which should be a novel biomarker for early diagnosis, treatment, and prognosis of RCC.
引用
收藏
页码：577 / 588
页数：12
相关论文
共 43 条
[1]   A phase I clinical trial of low-dose interferon-α-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma [J].
Amato, Robert J. ;
Khan, Muhammad .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (06) :1069-1073
[2]   Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature [J].
Bandini, Marco ;
Smith, Ariane ;
Marchioni, Michele ;
Pompe, Raisa S. ;
Martel, Tristan F. ;
Cindolo, Luca ;
Montorsi, Francesco ;
Shariat, Shahrokh F. ;
Briganti, Alberto ;
Kapoor, Anil ;
Capitanio, Umberto ;
Karakiewicz, Pierre I. .
CLINICAL GENITOURINARY CANCER, 2018, 16 (03) :176-183
[3]   TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer [J].
Banerjee, Rajat ;
Russo, Nickole ;
Liu, Min ;
Basrur, Venkatesha ;
Bellile, Emily ;
Palanisamy, Nallasivam ;
Scanlon, Christina S. ;
van Tubergen, Elizabeth ;
Inglehart, Ronald C. ;
Metwally, Tarek ;
Mani, Ram-Shankar ;
Yocum, Anastasia ;
Nyati, Mukesh K. ;
Castilho, Rogerio M. ;
Varambally, Sooryanarayana ;
Chinnaiyan, Arul M. ;
D'Silva, Nisha J. .
NATURE COMMUNICATIONS, 2014, 5
[4]   The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation [J].
Bianchi, Cristina ;
Meregalli, Chiara ;
Bombelli, Silvia ;
Di Stefano, Vitalba ;
Salerno, Francesco ;
Torsello, Barbara ;
De Marco, Sofia ;
Bovo, Giorgio ;
Cifola, Ingrid ;
Mangano, Eleonora ;
Battaglia, Cristina ;
Strada, Guido ;
Lucarelli, Giuseppe ;
Weiss, Robert H. ;
Perego, Roberto A. .
ONCOTARGET, 2017, 8 (69) :113502-113515
[5]   Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma [J].
Cella, David ;
Motzer, Robert J. ;
Rini, Brian I. ;
Cappelleri, Joseph C. ;
Ramaswamy, Krishnan ;
Hariharan, Subramanian ;
Arondekar, Bhakti ;
Bushmakin, Andrew G. .
VALUE IN HEALTH, 2018, 21 (12) :1413-1418
[6]   UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses [J].
Chandrashekar, Darshan S. ;
Bashel, Bhuwan ;
Balasubramanya, Sai Akshaya Hodigere ;
Creighton, Chad J. ;
Ponce-Rodriguez, Israel ;
Chakravarthi, Balabhadrapatruni V. S. K. ;
Varambally, Sooryanarayana .
NEOPLASIA, 2017, 19 (08) :649-658
[7]   Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance) [J].
Chen, Ronald C. ;
Choueiri, Toni K. ;
Feuilly, Marion ;
Meng, Jie ;
Lister, Johanna ;
Marteau, Florence ;
Falchook, Aaron D. ;
Morris, Michael J. ;
George, Daniel J. ;
Feldman, Darren R. .
CANCER, 2020, 126 (24) :5311-5318
[8]   Cancer incidence and mortality in China, 2013 [J].
Chen, Wanqing ;
Zheng, Rongshou ;
Zhang, Siwei ;
Zeng, Hongmei ;
Xia, Changfa ;
Zuo, Tingting ;
Yang, Zhixun ;
Zou, Xiaonong ;
He, Jie .
CANCER LETTERS, 2017, 401 :63-71
[9]   Cancer Statistics in China, 2015 [J].
Chen, Wanqing ;
Zheng, Rongshou ;
Baade, Peter D. ;
Zhang, Siwei ;
Zeng, Hongmei ;
Bray, Freddie ;
Jemal, Ahmedin ;
Yu, Xue Qin ;
He, Jie .
CA-A CANCER JOURNAL FOR CLINICIANS, 2016, 66 (02) :115-132
[10]  
Chin Arnold I, 2006, Rev Urol, V8, P1
12345